Go Pro
NASDAQ:INDP

Indaptus Therapeutics Q2 2025 Earnings Report

Indaptus Therapeutics logo
$3.55 -0.38 (-9.67%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$3.68 +0.14 (+3.80%)
As of 09/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Indaptus Therapeutics EPS Results

Actual EPS
-$9.09
Consensus EPS
-$0.36
Beat/Miss
Missed by -$8.73
One Year Ago EPS
N/A

Indaptus Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Indaptus Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Indaptus Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Indaptus Therapeutics Earnings Headlines

Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.tc pixel
See More Indaptus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email.

About Indaptus Therapeutics

Indaptus Therapeutics (NASDAQ:INDP) is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies. Its technology may also have applications in infectious diseases and other conditions where immune-system activation could provide a therapeutic benefit.

Indaptus Therapeutics is headquartered in New York and conducts research and clinical development activities through its biotechnology programs. The company’s work remains focused primarily on advancing its investigational immunotherapy candidates through clinical development and establishing their potential use across oncology and related therapeutic areas.

View Indaptus Therapeutics Profile